Project information
European consortium for communicating gene- and cell-based therapy information.
(EuroGCT)
- Project Identification
- 965241 EuroGCT
- Project Period
- 2/2021 - 1/2026
- Investor / Pogramme / Project type
-
European Union
- Horizon 2020
- Health, demographic change and wellbeing (Societal Challenges)
- MU Faculty or unit
- Faculty of Medicine
- Cooperating Organization
-
The University of Edinburgh
The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders. EuroGCT has two major objectives:
- To provide patients, people affected by conditions, healthcare professionals and citizens with accurate scientific, legal, ethical and societal information and with engagement opportunities, and thus to support better informed decisionmaking
related to cell and gene-based therapies.
- To facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by providing the research community and regulatory and healthcare authorities with an information source on
the practical steps needed for cell and gene therapy development.
To achieve our aims, EuroGCT will adopt a highly structured system for coordinated management of information related to cell and gene therapy development and, from this, will implement an ambitious programme of online and direct stakeholder
information provision and engagement. All outputs will be delivered in 7 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium
comprises leading cell and gene therapy-related organisations and basic and clinical research labs across Europe, including new member states; together with experts in product development, ethical, legal and societal issues, and in evaluating clinical outcomes; patient representatives; and science communicators. It thus is uniquely placed to develop a world-leading cell and gene therapy information resource and to meet the challenge outlined in Topic SC1-HCO-19-2020.